{"id":670288,"date":"2023-09-29T20:04:01","date_gmt":"2023-09-29T20:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=670288"},"modified":"2023-09-29T20:04:01","modified_gmt":"2023-09-29T20:04:01","slug":"cancer-pain-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-wex-pharma-sorrento-therapeutics-tetra-biopharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cancer-pain-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-wex-pharma-sorrento-therapeutics-tetra-biopharma_670288.html","title":{"rendered":"Cancer Pain Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies &#8211; Wex Pharma, Sorrento Therapeutics, Tetra Bio-Pharma"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cancer Pain Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Wex Pharma, Sorrento Therapeutics, Tetra Bio-Pharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Cancer Pain Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Wex Pharma, Sorrento Therapeutics, Tetra Bio-Pharma\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Cancer Pain &#8211; Market Insights, Epidemiology, and Market Forecast\u20132032\u2019 report delivers an in-depth understanding of Cancer Pain historical and forecasted epidemiology as well as the Cancer Pain market trends in the United States, EU4 (Germany, France, Italy and Spain), the UK, and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &lsquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cancer-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Cancer Pain &#8211; Market Insights, Epidemiology, and Market Forecast&ndash;2032<\/a><\/strong>&rsquo; report delivers an in-depth understanding of Cancer Pain historical and forecasted epidemiology as well as the Cancer Pain market trends in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Highlights of the Cancer Pain Market&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Key Companies working in the Cancer Pain market include Wex PharmaSorrento Therapeutics, Tetra Bio-Pharma, and many others&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Key Therapies working in the Cancer Pain&nbsp; market include Oxycodone and many others&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cancer Pain Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The International Association for the study of Pain defines pain as &ldquo;an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.&rdquo; Worldwide, many people are affected by cancer, and the prevalence is rising. Pain is the most typical symptom of cancer at diagnosis and rises in prevalence throughout and beyond cancer treatment and continues to be a major source of suffering in advanced cancer with adverse effects on patients&rsquo; life quality and caregiver distress. Cancer pain is a complex biological phenomenon that is poorly understood or classified. No specific and widely acceptable taxonomy of cancer pain exists. In any given patient, different mechanisms can be responsible for the pain. Recently, new perspectives on the biology of pain caused by tumor invasion have emerged.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/a7b2ba6e2b008c8332c2ee849a67fe06.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cancer Pain Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">In 2021, the total incident cases of cancer pain in the US were ~2,321,000 cases, which are anticipated to increase in 2032.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">EU4 and the UK, in 2021, accounted for ~2,278,000 cases of cancer pain, which are anticipated to increase by the year 2032.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Among the EU4 countries, the highest number of cases of cancer pain were found in Germany, i.e., ~634,000 cases in the year 2021, which are estimated to increase by the year 2032.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In 2021, the incident cases of breakthrough cancer pain were ~379,000 in France. These cases are expected to increase during the forecast period.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cancer-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Cancer Pain Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Report Covers the Cancer Pain Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cancer-diagnosed cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cancer Pain incident cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cancer Pain prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cancer Pain treatment cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cancer Pain Market Outlook&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Cancer subsumes many diseases, varied illness trajectories, and a rapidly changing therapeutic landscape. The burden of cancer-related illness is high for both patients and families, and symptom distress contributes substantially to this burden. Chronic pain is among the most important symptoms in terms of prevalence and potential consequences. Integrating best practices for pain management into humane, effective, and affordable cancer care is a key challenge for healthcare systems worldwide.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Pain is common in cancer patients, particularly in the advanced stage of the disease, when the prevalence is estimated to be &gt;70%, contributing to poor physical and emotional well-being. Increased survival with either life-prolonging or curative treatment results in increased numbers of patients experiencing persistent pain due to treatment, disease, or a combination of both. Approximately 5%&ndash;10% of cancer survivors have chronic severe pain that interferes significantly with functioning.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cancer-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Companies Working in the Cancer Pain Market<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Wex PharmaSorrento Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tetra Bio-Pharma<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cancer Pain Therapies Covered and Analyzed in the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oxycodone<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cancer-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Key Companies and Emerging Therapies in the Cancer Pain Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>&nbsp;Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cancer Pain Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Executive Summary of Cancer Pain&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Epidemiology and Patient Population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cancer Pain Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cancer Pain Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cancer-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Cancer Pain Market Outlook<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cancer-pain-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-wex-pharma-sorrento-therapeutics-tetra-biopharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cancer-pain-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-wex-pharma-sorrento-therapeutics-tetra-biopharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Cancer Pain &#8211; Market Insights, Epidemiology, and Market Forecast\u20132032\u2019 report delivers an in-depth understanding of Cancer Pain historical and forecasted epidemiology as well as the Cancer Pain market trends in the United States, EU4 (Germany, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cancer-pain-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-wex-pharma-sorrento-therapeutics-tetra-biopharma_670288.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-670288","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/670288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=670288"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/670288\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=670288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=670288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=670288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}